{"id":18504,"date":"2022-01-28T09:10:31","date_gmt":"2022-01-28T17:10:31","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18504"},"modified":"2022-01-28T09:10:32","modified_gmt":"2022-01-28T17:10:32","slug":"fda-clears-insulet-corp-s-automated-insulin-delivery-system","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/fda-clears-insulet-corp-s-automated-insulin-delivery-system\/","title":{"rendered":"FDA Clears Insulet Corp.’s Automated Insulin Delivery System"},"content":{"rendered":"\n
Insulet Corporation (NASDAQ: PODD) received <\/a>clearance from the U.S. Food and Drug Administration (FDA) for its Omnipod\u00ae 5 Automated Insulin Delivery System.<\/p>\n\n\n\n Shares of Insulet Corporation (NASDAQ: PODD) gained <\/a>over 12.9% during the premarket trading session following the announcement.\u00a0<\/p>\n\n\n\n The Omnipod 5, intended for individuals aged six years and older with type 1 diabetes, is designed to make it easier to manage glucose without multiple daily injections, tubes, or fingersticks.\u00a0<\/p>\n\n\n\n \u201cAs the pioneer of integrated CGM, we are excited to see our years of collaborative work with Insulet culminate into the first and only FDA-cleared tubeless automated insulin delivery system. Omnipod 5 combines the accuracy and unmatched user experience of the Dexcom G6 CGM with the simplicity of tubeless insulin delivery to offer people with diabetes a revolutionary new way to optimize time in range.\u201d<\/p>Kevin Sayer, Chairman, President and CEO of Dexcom<\/cite><\/blockquote>\n\n\n\n Omnipod 5 was a CES\u00ae 2022 Innovation Award honoree in two categories: Health and Wellness as well as Wearable Technologies, and in the near future, Insulet will offer Omnipod 5 in a limited market release. <\/p>\n","protected":false},"excerpt":{"rendered":"Insulet Corporation (NASDAQ: PODD) received clearance from the U.S. Food and Drug Administration (FDA) for its Omnipod\u00ae 5 Automated Insulin Delivery System. Up over 12% Shares of Insulet Corporation (NASDAQ: PODD) gained over 12.9% during the premarket trading session following the announcement.\u00a0 Type 1 Diabetes The Omnipod 5, intended for individuals aged six years and… View Article<\/a>","protected":false},"author":3,"featured_media":18024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nUp over 12%<\/h5>\n\n\n\n
Type 1 Diabetes<\/h5>\n\n\n\n